摘要
急性髓系白血病(acute myeloid leukemia,AML)是一类以造血干细胞分化减弱、克隆增殖、原始细胞大量聚集为特点的血液系统恶性肿瘤,与其他血液系统恶性肿瘤相比,AML近几十年仍无关键性药物被批准使用并从中获益,治疗上始终是以蒽环类药物为主的经典“7+3”诱导治疗方案。
Acute myeloid leukemia(AML)is a series of highly heterogeneous neoplasm,with the development of detections,whose current therapeutic goal is to realize molecular remission to prolong overall survival.Approximately 40% to 65% AML patients will subsequently relapse because of the residual leukemia cells termed minimal/measurable residual disease(MRD)appearing in bone marrow and peripheral blood.The techniques include flow cytometry(FCM),fluorescence in situ hybridization(FISH),quantitative real-time polymerase chain reaction(qPCR),next-generation sequencing technology(NGS)and so on.However,FISH and qPCR can sensitively indentify PML-RARαfusion gene in the diagnosis of 90%acute promyelocytic leukemia(APL)and has been applied to detect MRD widely.While in AML(not including APL),the methods of MRD are in no agreement.This paper reviews the progress of FCM,the most prevailing detection,in MRD assessment among AML(not including APL)patients.
出处
《临床血液学杂志》
CAS
2018年第6期878-881,共4页
Journal of Clinical Hematology
关键词
流式细胞术
急性髓系白血病
微小残留病灶
风险评估
flow cytometry
acute myeloid leukemia
minimal/measurable residual disease
risk assessment
